Oppenheimer analyst Leland Gershell assigned a Buy rating to Protara Therapeutics (TARA – Research Report) today and set a price target of $43.00. The company’s shares closed last Monday at $15.30, close to its 52-week low of $12.51.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 6.0% and a 38.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Protara Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $43.67.
Based on Protara Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.81 million. In comparison, last year the company had a GAAP net loss of $2.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ArTara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.